ETX-19477 for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 May 2024: Trial registered, NCT06395519
  2. 13 May 2024: Trial started, NCT06395519

The trials

NCT06395519: A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

State
Under way
Phase
Phase 1 and Phase 2
People
120 planned
Started
13 May 2024
Primary completion
Dec 2026
Arms
Phase 1 Part 1: Monotherapy Dose Escalation, Phase 1 Part 2: Monotherapy Dose Expansion
Results
None posted
  1. 2 May 2024: Trial registered
  2. 13 May 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.